List of Genetic Analysis/Screening Companies in Massachusetts - 23

Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than 70% of the top 50 pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.

Single-cell analysis company focused on the high-throughput identification and characterization of neoantigen-specific T-cell receptors.

Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression's OneRNA™ test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA's to approved therapies and clinical trials.

At Genospace, our mission is to deliver the platform that makes biomedical data useful and usable by everyone. Genospace has built a comprehensive platform for precision medicine to enable interpretation, analysis, reporting and collaboration on high-dimensional genomic and other biomedical data. With specific applications supporting research, development, pathology and clinical care, many of the most advanced precision medicine organizations are powered by Genospace. Please visit www.genospace.com for more information.

Honeycomb Biotechnologies is an early-stage company focused on making scalable solutions for storage and single cell genomic analysis of precious clinical samples. We enable translation of the rich biological information encoded in clinical specimens into high-resolution digital information, which can be queried and analyzed with sequencing. The resulting exponential growth in knowledge about the state of each person’s health and disease will enable the identification of new therapies and better targeting of current medicines in the era of precision medicine. Our first product is the “HIVE” – a single-use disposable device that is used (without any Honeycomb-specific instrumentation or equipment) for capturing, storing, and analyzing biological samples with single-cell resolution.

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage. For more information, please visit www.immuneering.com.

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

KBioBox is a Bioinformatics company that specializes in fast precision Off Target Analysis and Gene Edit BioDesign for genetic data.

Modalis Therapeutics Corporation (Tokyo Mothers 4883) is developing precision genetic medicines through epigenetic gene modulation. Modalis is advancing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or histone modification without the need for double- stranded DNA cleavage, gene editing or base editing. Modalis is headquartered in Tokyo with laboratories and R&D facilities in Cambridge,

Develops the LoopCap,™ a 4-step NGS workflow that removes the need for conventional library prep and generates a targeted, sequencer-ready library of molecules representing genomic regions of interest in a highly redundant manner.

As the leader in Decision Medicine™, Pillar’s technology platform drives significantly more efficient and accessible NGS testing with industry-leading accuracy and sensitivity. Pillar’s extensive portfolio applies across the entire patient journey, from profiling to therapy selection and monitoring, generating actionable insights to get patients on the right therapy faster In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.

PrecisionLife is the clinical-stage precision medicine company for complex chronic diseases. Creating better diagnostic tools and more personalized treatment options for patients with unmet medical needs. Our analytics and AI is unique in its understanding of causal disease biology. Identifying biomarkers to stratify patients by molecular mechanism of either their disease or drug response and link individuals to the drug targets, trials and treatments that will benefit them. With these insights we significantly increase the probability of success throughout the biopharma and healthcare value chain. Accelerating, informing and de-risking drug discovery and clinical development, building highly predictive diagnostics, and in launching more personalized and preventative medicines. To learn more, visit precisionlife.com.

Quintara Biosciences specializes in providing high quality DNA sequencing and genomic services for life science research communities around the world. With labs located in MA, CA, CO, CT, NJ, and DC, we are poised and ready to help scientists move their research forward.

Our Somatic Genomics platform unveils a new universe of genetic variation to create transformational medicines. Learn more at Quotient-Tx.com

Sage Science products are built on the idea that science is more robust and reliable when it is based on high-precision, automated, reproducible technology instead of manually intensive steps that introduce variability and error. We look at molecular biology workflows and identify high-value steps that can be significantly improved with accurate, automated solutions. Our products not only reduce hands-on time and boost throughput, but they also improve data quality and downstream results for life science and diagnostic labs. The Sage Science portfolio includes products to perform DNA or cDNA size selection: Pippin Prep for short-read NGS platforms and the BluePippin for short and long-read NGS platforms. The SageELF provides whole-sample fractionation of DNA for various applications. The SageHLS offers a new twist on DNA target enrichment. DNA is first extracted from cells directly on the platform. Then Cas9 endonuclease/guide RNA complexes are used to excise and collect large targets (entire genes or genomic regions, up to 500MB in length) from a genome. Large target enrichment, called CATCH (Cas9 assisted targeting of chromosomal segments) is used to elucidate difficult genomic structures such as pseudogenes, SVs, and repeat elements. Sage Science is privately funded. It is headquartered and manufactures at 500 Cummings Center in Beverly, MA, USA.

We are biotech company located in the Boston area, with a mission to revolutionize non-invasive diagnostics. The systems we are developing allow monitoring cancer patients'​ progress, as well as looking very early into pregnancy to gain a complete genetic picture of the fetus, all with a simple blood test.

SeqLL is a biotechnology company that specializes in Quantitative RNA & Specialty DNA Sequencing, offering True Single Molecule Sequencing technology.

seqWell was created to revolutionize NGS library prep to unlock the full potential of today’s DNA sequencing instruments. Our plexWell™ platform is a transformative library prep technology that allows for simple, scalable multiplexing of 100s to 1000s of samples without time- and cost-consuming normalization. plexWell has wide-ranging impact on applications from synthetic biology, targeted sequencing and single-cell analysis to low and high depth sequencing of human, plant, animal and microbial genomes. In addition to plexWell, seqWell is also developing library prep methods for reagent-based approaches for long-molecule phasing and read linking. We invite you to learn more at https://seqwell.com

Tessera Therapeutics is pioneering Gene Writing™—a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source.

Universal Sequencing Technology focuses on innovative Long-Read DNA Sequencing solutions. Our Tell-Seq technology simply turns a 2nd generation DNA sequencer into a 3rd gen, Long-Read Sequencer. The affordable TELL-Seq WGS library prep kit is used in Metagenomics, de novo Assembly, Whole Genome Phasing, and Structural Variant identification. We provide the kit and the analysis pipeline and all you need are the samples and some common lab equipment. No need to buy expensive 3rd generation sequencers. No need to buy droplet making equipment. No need to follow overly complicated protocols. No longer limited by genome size. The Tell-Seq WGS Library Prep kit is affordable without the added expense of an instrument. The protocol takes only 3 hours to run and can be used for genomes ranging from 1 Mb to 5 Gb. Again, this is Long-Read Sequencing Made Simple.

At Veritas, we apply science and our global resources to bring genetic and genomic diagnostics to people to extend and significantly improve their lives. Our global portfolio includes preventive medicine, perinatal medicine, and genomic diagnostic services. In March 2022 Veritas announced that it was becoming part of LetsGetChecked, a global healthcare solutions company based in Dublin and New York. In keeping with our responsibility as a leading biotechnology company, we collaborate with healthcare providers, governments, and local communities to support and expand access to genetic and genomic medicine reliably and affordably around the world.

Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation in genomics while providing unparalleled consistency. Volta is transforming the way biological research and analyses are performed, allowing scientists to focus on what they do best -- pushing the boundaries of biology. As a collective of scientists and builders working at the intersection of engineering and biology, we imagine a world where extracting vital information from biological samples is as simple as pressing a button. That's our vision, and we're turning it into reality. Our HQ is in Boston’s Seaport, where we develop and manufacture our technology. We believe in cross-functional collaboration and continuous learning – whether your interest is in biology, MechEng, CompEng, or simply joining a fast-growing startup striving to make the world a better place, we'd love to welcome you to our team. Check out some of our blog posts to learn more about work life at Volta.